Phase3

La phase 3 de l'étude mondiale INDIGO évaluera l'efficacité et l'innocuité de l'obéxélimab chez des patients atteints de la ML-IgG4, une maladie fibro-inflammatoire chronique et grave qui affecte généralement plusieurs organes La ML-IgG4…

CARLSBAD, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the first…

Tribune News Service Aditi Tandon New Delhi, August 15 Bharat Biotech on Monday announced that BBV154, India’s first intranasal Covid vaccine had…

The Serum Institute of India (SII) has sought permission from the country’s drug regulator to conduct Phase-3 trial to evaluate the safety and immunogenicity of its COVID-19 vaccine Covovax as a booster dose in children aged two to 18…

The Drugs Controller General Of India has already approved Covovax for restricted use in emergency situations in adults on December 28 An expert panel of India’s central drug authority has recommended permission for conducting a phase-3…

The Drugs Controller General Of India (DCGI) had approved Covovax for restricted use in emergency situations in adults on December 28. The vaccine is yet to be included in the country’s inoculation programme. Serum Institute of India has…

An average voter turnout of 63.44 per cent was recorded in Punjab while Uttar Pradesh, in its third phase of the Assembly elections, witnessed an average voter turnout of 57.43 per cent till 5 pm on Sunday. In Punjab, the highest voter…

Bharat Biotech’s nasal vaccine, BBV154, has already completed Phase-2 trials with Covaxin. The proposed Ph-3 trials will cover those who have been administered with any two doses of the Covid-19 vaccine. Vaccine maker Bharat Biotech has…

An intranasal vaccine as a booster dose would be easier to administer in mass vaccination campaigns and has the potential to prevent transmission. Bharat Biotech has sought the Drug Controller General of India’s approval to conduct…

Covaxin was developed with seed strains received from the National Institute of Virology and the Phase-3 clinical trials have been co-funded by the ICMR.The Drug Controller General of India (DCGI) on Tuesday accepted the 77.8% efficacy of…